Characterization of glioma stem cells through multiple stem cell markers and their specific sensitization to double-strand break-inducing agents by pharmacological inhibition of ataxia telangiectasia mutated protein

Brain Pathology

Volumn 22, Issue 5, 2012, Pages 677-688

  Raso, Alessandro ^a   Vecchio, Donatella ^b   Cappelli, Enrico ^a   Ropolo, Monica ^b   Poggi, Alessandro ^b   Nozza, Paolo ^a   Biassoni, Roberto ^a   Mascelli, Samantha ^a   Capra, Valeria ^a   Kalfas, Fotios ^c   Severi, Paolo ^c   Frosina, Guido ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

brain tumor; cell cycle; glioblastoma; radiotherapy; resistance

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; KU 60019; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER STEM CELL; DOUBLE STRANDED DNA BREAK; FLOW CYTOMETRY; GLIOMA; HUMAN; HUMAN CELL; PHENOTYPE; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ATAXIA TELANGIECTASIA; CELL LINE, TUMOR; DNA BREAKS, DOUBLE-STRANDED; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INTERMEDIATE FILAMENT PROTEINS; KARYOTYPING; MUTATION; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; NEUROBLASTOMA; RADIATION, IONIZING;

EID: 84865509913     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2012.00566.x     Document Type: Article

References (24)

1. Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G, (2009) BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci 29: 8884-8896.
2. Arienti KL, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, et al, (2005) Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem 48: 1873-1885. (Pubitemid 40396318)
3. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al, (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756-760. (Pubitemid 44949604)
4. Bidlingmaier S, Zhu X, Liu B, (2008) The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 86: 1025-1032.
5. Bolderson E, Richard DJ, Zhou BB, Khanna KK, (2009) Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair. Clin Cancer Res 15: 6314-6320.
6. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al, (2009) The MIQE guidelines: Minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
7. Chen CC, Kennedy RD, Sidi S, Look AT, D'Andrea A, (2009) CHK1 inhibition as a strategy for targeting fanconi anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8: 24.
8. Frosina G, (2009) DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol Cancer Res 7: 989-999.
9. Frosina G, (2011) Frontiers in targeting glioma stem cells. Eur J Cancer 47: 496-507.
10. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al, (2009) Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 8: 2894-2902.
11. Hermansen SK, Christensen KG, Jensen SS, Kristensen BW, (2011) Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem 59: 391-407.
12. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NM, Orr AI, et al, (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159. (Pubitemid 39665530)
13. Jaspers NG, de Wit J, Regulski MR, Bootsma D, (1982) Abnormal regulation of DNA replication and increased lethality in ataxia telangiectasia cells exposed to carcinogenic agents. Cancer Res 42: 335-341. (Pubitemid 12207288)
14. Kaneko Y, Sakakibara S, Imai T, Suzuki A, Nakamura Y, Sawamoto K, et al, (2000) Musashi1: An evolutionally conserved marker for CNS progenitor cells including neural stem cells. Dev Neurosci 22: 139-153. (Pubitemid 30098914)
15. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, et al, (2008) Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62: 505-514. Discussion 514-515. (Pubitemid 351489297)
16. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
17. Raso A, Negri F, Gregorio A, Nozza P, Mascelli S, De Marco P, et al, (2008) Successful isolation and long-term establishment of a cell line with stem cell-like features from an anaplastic medulloblastoma. Neuropathol Appl Neurobiol 34: 306-315. (Pubitemid 351590865)
18. Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, et al, (2011) High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro Oncol 13: 500-508.
19. Ropolo M, Daga A, Griffero F, Foresta M, Casartelli G, Zunino A, et al, (2009) Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 7: 383-392.
20. Tatard VM, Xiang C, Biegel JA, Dahmane N, (2010) ZNF238 is expressed in postmitotic brain cells and inhibits brain tumor growth. Cancer Res 70: 1236-1246.
21. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ, (2010) Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166-193.
22. Viaggi S, Abbondandolo A, Carbone M, Ottaggio L, Sessarego M, Zupo S, Zunino A, (2004) Uncommon cytogenetic findings in a case of splenic marginal zone lymphoma with aggressive clinical course. Cancer Genet Cytogenet 148: 133-136. (Pubitemid 38083341)
23. Wan F, Zhang S, Xie R, Gao B, Campos B, Herold-Mende C, Lei T, (2010) The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 20: 877-889.
24. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J, (2008) Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res 27: 85.